ABOUT BRIACELL
BriaCell (TSXV: BCT) (OTCQB: BCTXF) is a clinical stage immuno-oncology focused biotechnology company developing the first off the shelf personalized immunotherapy for cancer. The company is conducting a Phase IIa clinical trial for its lead product candidate, Bria-IMT™, in advanced breast cancer along with the co-development of BriaDX™, its companion diagnostic. Additionally, there is an FDA approved combination study of Bria-IMT™ with pembrolizumab or ipilimumab for patients with advanced breast cancer previously treated with Bria-IMT™. Moreover, BriaCell is developing Bria-OTS™, the first “off the shelf†personalized treatment for advanced stage Breast Cancer. BriaCell's small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases. For additional information on BriaCell, please visit our website: http://briacell.com/